← All trials
NCT05541952
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2022
- Primary completion
- Jul 25, 2023
- Completion date
- Dec 31, 2025
- First posted
- Sep 15, 2022
- Last posted
- Sep 26, 2022
- Enrollment
- 760
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Federal University of Mato Grosso do SulLead sponsor
- Federal University of Mato Grosso do SulOverall official - principal investigator
- Federal University of Mato Grosso do SulReponsible party - principal investigator
- Stanford UniversityCollaborator
- Oswaldo Cruz FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.